vs
Protalix BioTherapeutics, Inc.（PLX）与Rhinebeck Bancorp, Inc.（RBKB）财务数据对比。点击上方公司名可切换其他公司
Rhinebeck Bancorp, Inc.的季度营收约是Protalix BioTherapeutics, Inc.的1.5倍（$13.5M vs $9.1M），Rhinebeck Bancorp, Inc.净利率更高（17.3% vs -60.3%，领先77.6%），Rhinebeck Bancorp, Inc.同比增速更快（1701.1% vs -49.9%），Rhinebeck Bancorp, Inc.自由现金流更多（$10.9M vs $1.6M），过去两年Rhinebeck Bancorp, Inc.的营收复合增速更高（14.0% vs -6.7%）
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
Rhinebeck Bancorp, Inc.是总部位于美国纽约的区域性银行控股企业，旗下运营莱茵贝克银行，主要面向纽约哈德逊谷地区的个人消费者与中小企业提供储蓄、贷款、抵押贷款、财富管理等零售及商业金融服务。
PLX vs RBKB — 直观对比
营收规模更大
RBKB
是对方的1.5倍
$9.1M
营收增速更快
RBKB
高出1751.0%
-49.9%
净利率更高
RBKB
高出77.6%
-60.3%
自由现金流更多
RBKB
多$9.3M
$1.6M
两年增速更快
RBKB
近两年复合增速
-6.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $9.1M | $13.5M |
| 净利润 | $-5.5M | $2.3M |
| 毛利率 | 49.4% | — |
| 营业利润率 | -51.1% | 21.7% |
| 净利率 | -60.3% | 17.3% |
| 营收同比 | -49.9% | 1701.1% |
| 净利润同比 | -184.8% | 188.0% |
| 每股收益（稀释后） | $-0.06 | $0.21 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PLXRBKB
| Q4 25 | $9.1M | $13.5M | ||
| Q3 25 | $17.9M | $14.0M | ||
| Q2 25 | $15.7M | $13.1M | ||
| Q1 25 | $10.1M | $12.8M | ||
| Q4 24 | $18.2M | $750.0K | ||
| Q3 24 | $18.0M | $773.0K | ||
| Q2 24 | $13.5M | $10.7M | ||
| Q1 24 | — | $10.4M |
净利润PLXRBKB
| Q4 25 | $-5.5M | $2.3M | ||
| Q3 25 | $2.4M | $2.7M | ||
| Q2 25 | $164.0K | $2.7M | ||
| Q1 25 | $-3.6M | $2.3M | ||
| Q4 24 | $6.5M | $-2.7M | ||
| Q3 24 | $3.2M | $-8.1M | ||
| Q2 24 | $-2.2M | $975.0K | ||
| Q1 24 | — | $1.1M |
毛利率PLXRBKB
| Q4 25 | 49.4% | — | ||
| Q3 25 | 53.4% | — | ||
| Q2 25 | 62.5% | — | ||
| Q1 25 | 19.1% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 53.4% | — | ||
| Q2 24 | 29.8% | — | ||
| Q1 24 | — | — |
营业利润率PLXRBKB
| Q4 25 | -51.1% | 21.7% | ||
| Q3 25 | 11.9% | 23.9% | ||
| Q2 25 | 7.5% | 26.6% | ||
| Q1 25 | -41.0% | 22.9% | ||
| Q4 24 | 39.6% | -444.9% | ||
| Q3 24 | 22.2% | -1332.3% | ||
| Q2 24 | -18.0% | 11.8% | ||
| Q1 24 | — | 13.9% |
净利率PLXRBKB
| Q4 25 | -60.3% | 17.3% | ||
| Q3 25 | 13.2% | 19.3% | ||
| Q2 25 | 1.0% | 20.8% | ||
| Q1 25 | -35.8% | 17.9% | ||
| Q4 24 | 35.6% | -353.9% | ||
| Q3 24 | 18.0% | -1042.9% | ||
| Q2 24 | -16.4% | 9.2% | ||
| Q1 24 | — | 10.8% |
每股收益（稀释后）PLXRBKB
| Q4 25 | $-0.06 | $0.21 | ||
| Q3 25 | $0.03 | $0.25 | ||
| Q2 25 | $0.00 | $0.25 | ||
| Q1 25 | $-0.05 | $0.21 | ||
| Q4 24 | $0.10 | $-0.24 | ||
| Q3 24 | $0.03 | $-0.75 | ||
| Q2 24 | $-0.03 | $0.09 | ||
| Q1 24 | — | $0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $14.7M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $48.2M | $136.9M |
| 总资产 | $82.3M | $1.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PLXRBKB
| Q4 25 | $14.7M | — | ||
| Q3 25 | $13.6M | — | ||
| Q2 25 | $17.9M | — | ||
| Q1 25 | $19.5M | — | ||
| Q4 24 | $19.8M | — | ||
| Q3 24 | $27.4M | — | ||
| Q2 24 | $23.4M | — | ||
| Q1 24 | — | — |
股东权益PLXRBKB
| Q4 25 | $48.2M | $136.9M | ||
| Q3 25 | $52.9M | $133.0M | ||
| Q2 25 | $49.9M | $129.0M | ||
| Q1 25 | $45.2M | $126.0M | ||
| Q4 24 | $43.2M | $121.8M | ||
| Q3 24 | $32.4M | $122.7M | ||
| Q2 24 | $28.6M | $116.2M | ||
| Q1 24 | — | $114.3M |
总资产PLXRBKB
| Q4 25 | $82.3M | $1.3B | ||
| Q3 25 | $82.3M | $1.3B | ||
| Q2 25 | $78.5M | $1.3B | ||
| Q1 25 | $73.9M | $1.3B | ||
| Q4 24 | $73.4M | $1.3B | ||
| Q3 24 | $61.6M | $1.3B | ||
| Q2 24 | $91.5M | $1.3B | ||
| Q1 24 | — | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.0M | $11.7M |
| 自由现金流经营现金流 - 资本支出 | $1.6M | $10.9M |
| 自由现金流率自由现金流/营收 | 17.8% | 80.6% |
| 资本支出强度资本支出/营收 | 4.4% | 6.3% |
| 现金转化率经营现金流/净利润 | — | 5.03× |
| 过去12个月自由现金流最近4个季度 | $-13.6M | $19.4M |
8季度趋势，按日历期对齐
经营现金流PLXRBKB
| Q4 25 | $2.0M | $11.7M | ||
| Q3 25 | $-3.7M | $2.2M | ||
| Q2 25 | $-5.2M | $2.4M | ||
| Q1 25 | $-5.1M | $4.3M | ||
| Q4 24 | $4.0M | $8.5M | ||
| Q3 24 | $4.1M | $-3.6M | ||
| Q2 24 | $-3.6M | $12.0M | ||
| Q1 24 | — | $-3.5M |
自由现金流PLXRBKB
| Q4 25 | $1.6M | $10.9M | ||
| Q3 25 | $-4.2M | $2.0M | ||
| Q2 25 | $-5.7M | $2.2M | ||
| Q1 25 | $-5.4M | $4.2M | ||
| Q4 24 | $3.6M | $7.7M | ||
| Q3 24 | $4.0M | $-3.6M | ||
| Q2 24 | $-3.8M | $11.8M | ||
| Q1 24 | — | $-3.7M |
自由现金流率PLXRBKB
| Q4 25 | 17.8% | 80.6% | ||
| Q3 25 | -23.7% | 14.5% | ||
| Q2 25 | -36.2% | 17.2% | ||
| Q1 25 | -53.0% | 32.8% | ||
| Q4 24 | 19.6% | 1023.9% | ||
| Q3 24 | 22.4% | -469.0% | ||
| Q2 24 | -28.1% | 111.1% | ||
| Q1 24 | — | -36.0% |
资本支出强度PLXRBKB
| Q4 25 | 4.4% | 6.3% | ||
| Q3 25 | 2.8% | 1.4% | ||
| Q2 25 | 2.8% | 1.4% | ||
| Q1 25 | 3.0% | 0.9% | ||
| Q4 24 | 2.3% | 105.5% | ||
| Q3 24 | 0.5% | 6.3% | ||
| Q2 24 | 1.3% | 1.2% | ||
| Q1 24 | — | 2.3% |
现金转化率PLXRBKB
| Q4 25 | — | 5.03× | ||
| Q3 25 | -1.58× | 0.83× | ||
| Q2 25 | -31.91× | 0.89× | ||
| Q1 25 | — | 1.89× | ||
| Q4 24 | 0.61× | — | ||
| Q3 24 | 1.27× | — | ||
| Q2 24 | — | 12.27× | ||
| Q1 24 | — | -3.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
RBKB
暂无分部数据
